Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058138 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL15058137 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21073334 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21073336 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL18660256 | 0.88 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21311372 | 0.81 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL28175927 | 0.81 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21071878 | 0.81 | GPR119 (0.38) | CHRM2CHRM1CHRM3HSD17B10MEN1 | |
| SCHEMBL21072584 | 0.81 | GPR119 (0.38) | CHRM2CHRM1CHRM3HSD17B10MEN1 | |
| SCHEMBL21071881 | 0.81 | GPR119 (0.38) | CHRM2CHRM1CHRM3HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3728207-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| EP-2794608-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| EP-2794608-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2674434-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013091773-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | CHRM2 4841/4885CHRM1 4852/4885CHRM3 4785/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CHRM2 4842/4885CHRM1 4617/4885CHRM3 4710/4885 |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CHRM2 4842/4885CHRM1 4617/4885CHRM3 4710/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CHRM2 4842/4885CHRM1 4617/4885CHRM3 4710/4885 |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CHRM2 4842/4885CHRM1 4617/4885CHRM3 4710/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CHRM2 4842/4885CHRM1 4617/4885CHRM3 4710/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | CHRM2 4842/4885CHRM1 4617/4885CHRM3 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.